CoChat

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 4 of the 19 sources its claims cite were checked for support.

Abstract

Background: In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a multi-omic correlative analysis of actionable biomarkers. Methods: Patients were randomized (non-comparative) to receive either N or N+I. The primary endpoint was a 6-month confirmed response rate (CRR) defined by Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints included treatment-related adverse events (TRAEs), progression-free survival, and overall survival. Multi-omic correlative analyses were conducted using samples from both the primary and expansion cohorts. Results: A total of 66 patients were evaluated for the primary endpoint with disease including gastrointestinal stromal tumor (GIST, n=18), undifferentiated pleomorphic sarcoma (UPS, n=24), and dedifferentiated liposarcoma (DDLPS, n=24). Neither N nor N+I achieved a complete or partial response in the GIST expansion cohort. In DDLPS and UPS, the primary response endpoint of CRR was met with N+I (both 16.6%, 2/12) but not with N alone (both 8.3%, 1/12). In the GIST cohort, TRAE was higher with N+I treatment, halting enrollment as required per protocol. In a correlative analysis of patients for the expansion cohort and the original cohort (n=86), traditional biomarkers of immunotherapy response were not correlated with response in any histological subtype. Markers of genomic instability including the presence of gene fusions and increased subclonal mutations correlated with improved clinical outcomes. Conclusions: This expansion cohort reaffirms the outcomes of A091401. There remains a pressing need to determine the role of and predictive biomarkers for immunotherapy in sarcoma. Trial registration number: NCT02500797.

Overview

CoChat Summary

TL;DR

This phase II expansion of Alliance A091401 found confirmed activity of nivolumab plus ipilimumab, but not nivolumab alone, in dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS), while gastrointestinal stromal tumors (GIST) had no confirmed responses. Exploratory correlative analyses found no association for standard immune biomarkers, but did find signals for genomic instability markers, especially gene fusions and subclonal mutations.

Key findings

  • In the expansion cohort, confirmed response rate (CRR) met the prespecified threshold for promise in DDLPS and UPS with nivolumab + ipilimumab: 2/12 (16.6%) in the primary analysis for each histology; nivolumab alone was 1/12 (8.3%) in each.
  • In the full treated cohorts, CRR was 0% (0/10) for GIST with nivolumab and 0% (0/11) with nivolumab + ipilimumab; no confirmed responses occurred in GIST.
  • Secondary endpoints showed median PFS/OS, respectively:
  • DDLPS: nivolumab 4.6 months PFS, 8.1 months OS; nivolumab + ipilimumab 5.5 months PFS, 14.6 months OS.
  • UPS: nivolumab 1.4 months PFS, 6.6 months OS; nivolumab + ipilimumab 2.7 months PFS, 15.2 months OS.
  • GIST: nivolumab 1.5 months PFS, 9.1 months OS; nivolumab + ipilimumab 2.9 months PFS, 12.2 months OS.
  • Among exploratory biomarkers, PD-L1 expression was not associated with response, TMB was low (median 1.7 Mut/Mb; high TMB >10 Mut/Mb in n=1), and no tumors were MSI-high; by contrast, presence of any gene fusion was associated with PFS ≥12 weeks (p=0.01) and longer PFS (HR 0.20, 95% CI 0.08–0.51, p<0.001) and OS (HR 0.29, 95% CI 0.12–0.71, p=0.006).
  • In DDLPS, a higher proportion of subclonal mutations was associated with better outcomes: high subclonal fraction was linked to improved PFS (HR 0.27, 95% CI 0.09–0.83, p=0.003) and OS (HR 0.26, 95% CI 0.08–0.85, p=0.01).

Methods

  • Multicenter, unblinded, randomized, non-comparative phase II expansion cohorts of GIST, DDLPS, and UPS; patients were assigned 1:1 to nivolumab or nivolumab + ipilimumab, and each treatment arm/tumor type was treated as an independent trial.
  • Eligible patients were ≥18 years, had locally advanced/unresectable/metastatic disease, measurable disease by RECIST 1.1, ECOG 0–1, prior systemic therapy, and no prior anti-PD-1/PD-L1/CTLA-4 therapy; 79 patients registered and 77 started treatment.
  • Primary endpoint was confirmed objective response rate (CRR); secondary endpoints were duration of response, clinical benefit rate, PFS, and OS. Exploratory correlative analyses used pretreatment tissue from 86 patients (with 82 evaluable after exclusions), including IHC, DNA sequencing, RNA-seq, fusion calling, TMB, clonality, and pathway analysis, with 12-week PFS as the screening correlative endpoint.

Limitations

  • The paper states the study was not designed to make direct comparisons between nivolumab and nivolumab + ipilimumab, so any impression of greater activity for combination therapy is not statistically comparable.
  • The correlative analysis was exploratory, and the authors note the low response rate limited power; they state further study is needed in larger cohorts.
  • Evident from the text: sample sizes were small and uneven by histology, with only 30 tumors analyzed by RNA-seq and 86 total patients entering correlative analyses, which limits subtype-level inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/jitc-2024-009472

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Response to immunotherapy. Swimmers plot for patients in the expansion cohort who received either nivolumab alone or nivolumab in combination with ipilimumab by histological subtype of sarcoma. Vertical dashed lines represent the 6-week and 12-week restaging. Squares, empty or filled in, represent suspected and confirmed progressive disease, respectively. At the time the data were frozen for this analysis, all patients were no longer actively receiving study treatment. Diamonds represent objective responses. DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; UPS, undifferentiated pleomorphic sarcoma.
Figure 1 Response to immunotherapy. Swimmers plot for patients in the expansion cohort who received either nivolumab alone or nivolumab in combination with ipilimumab by histological subtype of sarcoma. Vertical dashed lines represent the 6-week and 12-week restaging. Squares, empty or filled in, represent suspected and confirmed progressive disease, respectively. At the time the data were frozen for this analysis, all patients were no longer actively receiving study treatment. Diamonds represent objective responses. DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; UPS, undifferentiated pleomorphic sarcoma.CC BY-NC · PubMed Central
Figure 2 Fusion-positive soft-tissue sarcomas were associated with improved survival outcomes across histologies. (A) Fusions were more prevalent across all tumors demonstrating PFS ≥12 weeks. (B,C) Across all histologies, the presence of a fusion (n=17) was associated with an improved PFS (HR 0.20, 95% CI 0.08–0.51, p=0.0008, (B) and OS (HR 0.29, 95% CI 0.12–0.71, p=0.006, (C) compared with patients’ tumors that did not demonstrate a fusion (n=13). DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; OS, overall survival; PFS, progression-free survival; UPS, undifferentiated pleomorphic sarcoma.
Figure 2 Fusion-positive soft-tissue sarcomas were associated with improved survival outcomes across histologies. (A) Fusions were more prevalent across all tumors demonstrating PFS ≥12 weeks. (B,C) Across all histologies, the presence of a fusion (n=17) was associated with an improved PFS (HR 0.20, 95% CI 0.08–0.51, p=0.0008, (B) and OS (HR 0.29, 95% CI 0.12–0.71, p=0.006, (C) compared with patients’ tumors that did not demonstrate a fusion (n=13). DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; OS, overall survival; PFS, progression-free survival; UPS, undifferentiated pleomorphic sarcoma.CC BY-NC · PubMed Central
Figure 3 Prevalence of subclonal mutations confer survival advantage in dedifferentiated liposarcoma (DDLPS). (A) The proportion of genomic variants predicted to be subclonal in DDLPS was higher in responsive compared with non-responsive tumors. (B) Total mutation count was similar in DDLPS despite tumor response. (C) Progression-free survival (PFS) was improved in patients whose tumors demonstrated a greater than median proportion of subclonal mutations (HR 0.27, (95% CI 0.089–0.83, p=0.003). (D) Multivariate analysis for PFS of subclonal mutation proportion, study arm, and total mutations. (C) Overall survival (OS) was improved in patients whose tumors demonstrated a greater than median proportion of subclonal mutations (HR 0.26, 95% CI 0.08–0.85, p=0.01). (D) Multivariate analysis for OS of subclonal mutation proportion, study arm, and total mutations. *p<0.05, ns: not significant.
Figure 3 Prevalence of subclonal mutations confer survival advantage in dedifferentiated liposarcoma (DDLPS). (A) The proportion of genomic variants predicted to be subclonal in DDLPS was higher in responsive compared with non-responsive tumors. (B) Total mutation count was similar in DDLPS despite tumor response. (C) Progression-free survival (PFS) was improved in patients whose tumors demonstrated a greater than median proportion of subclonal mutations (HR 0.27, (95% CI 0.089–0.83, p=0.003). (D) Multivariate analysis for PFS of subclonal mutation proportion, study arm, and total mutations. (C) Overall survival (OS) was improved in patients whose tumors demonstrated a greater than median proportion of subclonal mutations (HR 0.26, 95% CI 0.08–0.85, p=0.01). (D) Multivariate analysis for OS of subclonal mutation proportion, study arm, and total mutations. *p<0.05, ns: not significant.CC BY-NC · PubMed Central
Figure 4 Summary of findings across the cohort. N+I outperformed N for PFS (A) and trended towards improved OS (B). OS, overall survival; PFS, progression-free survival.
Figure 4 Summary of findings across the cohort. N+I outperformed N for PFS (A) and trended towards improved OS (B). OS, overall survival; PFS, progression-free survival.CC BY-NC · PubMed Central

Verification

Claims the paper makes

2 Valid · 1 Not valid · 11 Not checked · 102 Own results and interpretations

55 more claims

Create a free account to see all 116 claims and to verify the 15 references still open.

See all claims — free account
  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 41

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 54 references

Cited by

See all 24

Metadata

Authors
Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., Tap, W. D., Schwartz, G. K., George, S., & D'Angelo, S. P.
Affiliations
  • University of Florida (US)
  • The Ohio State University (US)
  • Mayo Clinic (US)
  • Washington University in Saint Louis, Saint Louis, Missouri, USA
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Iowa (US)
  • National Institutes of Health (US)
  • Case Western Reserve University (US)
  • Dana-Farber Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2024-09
Volume
12
Issue
9
Pages
e009472
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4402951295
Cited by
21
References
54
Citations by year
2026: 11 · 2025: 10
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cycle for Survival (n/a)
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology (n/a)
  • National Cancer Institute of the National Institutes of Health (P30CA08748, U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233290, UG1CA233331, UG1CA233339)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
nivolumab, ipilimumab, metastatic sarcoma, immune checkpoint inhibitors, combination immunotherapy, gastrointestinal stromal tumor, malignant fibrous histiocytoma, dedifferentiated liposarcoma, predictive biomarkers, genomic instability, gene fusion, subclonal mutations, treatment-related adverse events
MeSH terms
Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Sarcoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. https://app.cochat.ai/papers/10.1136/jitc-2024-009472
The paper
Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., Tap, W. D., Schwartz, G. K., George, S., & D'Angelo, S. P. (2024). A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009472

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.